Permanent Capital Management LP Makes New Investment in AbbVie Inc. $ABBV

Permanent Capital Management LP acquired a new stake in AbbVie Inc. (NYSE:ABBV) during the third quarter, HoldingsChannel reports. The firm acquired 3,109 shares of the company’s stock, valued at approximately $720,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Marshall & Sullivan Inc. WA purchased a new position in AbbVie in the second quarter valued at approximately $25,000. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the 2nd quarter worth approximately $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie in the 2nd quarter valued at $28,000. Financial Gravity Companies Inc. purchased a new position in shares of AbbVie in the 2nd quarter valued at $36,000. Finally, Delos Wealth Advisors LLC purchased a new position in shares of AbbVie in the 2nd quarter valued at $39,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.1%

ABBV opened at $230.07 on Monday. The business has a 50 day moving average price of $226.73 and a two-hundred day moving average price of $212.72. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The company has a market cap of $406.63 billion, a PE ratio of 174.30, a P/E/G ratio of 1.31 and a beta of 0.36. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 496.97%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of research reports. Citigroup reduced their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. JPMorgan Chase & Co. boosted their target price on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. HSBC raised AbbVie from a “hold” rating to a “buy” rating and upped their target price for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Finally, Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.